Lysobact Complete Spray sa aromom narandže i limuna 20 mg/1 mL+ 1,5 mg/1 mL+ 0,5 mg/1 mL sprej za usnu sluznicu, otopina Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lysobact complete spray sa aromom narandže i limuna 20 mg/1 ml+ 1,5 mg/1 ml+ 0,5 mg/1 ml sprej za usnu sluznicu, otopina

bosnalijek d.d. - cetilpiridin, lidokain, lizozim - sprej za usnu sluznicu, otopina - 20 mg/1 ml+ 1,5 mg/1 ml+ 0,5 mg/1 ml - 1 ml rastvora sadrži: 20 mg lizozim hidroklorida 1,5 mg cetilpiridin hlorida 0,5 mg lidokain hidrohlorida

Lysobact Complete Spray sa aromom narandže i limuna 20 mg/1 mL+ 1,5 mg/1 mL+ 0,5 mg/1 mL sprej za usnu sluznicu, otopina Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

lysobact complete spray sa aromom narandže i limuna 20 mg/1 ml+ 1,5 mg/1 ml+ 0,5 mg/1 ml sprej za usnu sluznicu, otopina

bosnalijek d.d. - cetilpiridin, lidokain, lizozim - sprej za usnu sluznicu, otopina - 20 mg/1 ml+ 1,5 mg/1 ml+ 0,5 mg/1 ml - 1 ml rastvora sadrži: 20 mg lizozim hidroklorida, 1,5 mg cetilpiridin hlorida, 0,5 mg lidokain hidrohlorida

STREPSILS narandža sa vitaminom C 0.6 mg/1 Pastila, Lozenga+ 1.2 mg/1 Pastila, Lozenga+ 100 mg/1 Pastila, Lozenga pastila Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

strepsils narandža sa vitaminom c 0.6 mg/1 pastila, lozenga+ 1.2 mg/1 pastila, lozenga+ 100 mg/1 pastila, lozenga pastila

ataco d.o.o. mostar - od 2,4-dihlorbenzil алькохол, amilmetakrezol, askorbinska kiselina - pastila - 0.6 mg/1 pastila, lozenga+ 1.2 mg/1 pastila, lozenga+ 100 mg/1 pastila, lozenga - 1 pastila sadrži: 0,6 mg amilmetakrezola 1,2 mg 2,4dihlorbenzil alkohola 100 mg vitamina c (kao askorbinska kiselina i natrijumaskorbat)

Comirnaty Europska Unija - hrvatski - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Spikevax (previously COVID-19 Vaccine Moderna) Europska Unija - hrvatski - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Tractocile Europska Unija - hrvatski - EMA (European Medicines Agency)

tractocile

ferring pharmaceuticals a/s - atosiban (as acetate) - prerano rođenje - drugi gynecologicals - tractotile ukazuje na kašnjenje neizbježan prerano poroda u trudnica odrasle žene:redovite kontrakcije maternice u trajanju od najmanje 30 sekundi trajanja u iznosu od ≥ 4 30 minuta;grlića maternice od 1 do 3 cm (0-3 za nulliparas) i стертость ≥ 50%;gestacijski u dobi od 24 do 33 punih tjedana trudnoće;normalan puls fetusa.

Saphnelo Europska Unija - hrvatski - EMA (European Medicines Agency)

saphnelo

astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.